Compare Hims and Hers Health Inc (HIMS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Zoetis Inc — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.6× Hims and Hers Health Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Zoetis Inc for 70 Days on average.
| HIMS | ZTS | |
|---|---|---|
Market Cap | $6.55B | $30.20B |
Volume | 14,842,814 | 6,175,327 |
Sector | Health | Health |
52-Week High | $62.76 | $147.53 |
52-Week Low | $14.52 | $69.09 |
Typical Hold Time | 21 Days | 70 Days |
Enterprise Value | $7.25B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
